May 5, 2025

Dear Colleague, 

The FDA works to safeguard the public against potential health risks, ensures the safety and efficacy of medical products, and the safety of our nation’s food supply and cosmetics.  Your partnership, knowledge and engagement in the public health space are appreciated. 

Sincerely,

The Public Engagement Staff
Public Engagement Staff | FDA

Updates

• FDA Patient Listening Sessions Webpages
• FY 2024 GDUFA Science and Research Report
• Registration & Listing of Cosmetic Product Facilities and Products

Consumer Updates

Is Rinsing Your Sinuses with Neti Pots Safe?

Little teapots with long spouts have become a fixture in many homes to flush out clogged nasal passages and help people breathe easier.  Along with other nasal irrigation devices, these devices — commonly called neti pots — use a saline, or saltwater, solution to treat congested sinuses, colds, and allergies.  They’re also used to moisten nasal passages exposed to dry indoor air.  But be careful.  Improper use of these neti pots and other nasal irrigation devices can increase your risk of infection.

Guidance Documents

• Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
• Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)

View all Official FDA Guidance Documents and other Regulatory Guidance

You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.

ICYMI!

Interactive and Social Media

A listing of social media, videos, podcasts, and more that are available from FDA.  Stay informed and connected with FDA through video, social media, e-mail alerts, and more.

Webinars and Virtual Workshops

UPDATED MEETING DATE AND PUBLIC PARTICIPATION INFORMATION: May 5, 2025 Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement

Mon, May 5, 2025; 8:00 a.m. - 5:00 p.m. ET

The Committees will discuss the findings of the completed ER/LA OA PMRs 3033-1 and 3033-2 (link to Release and Reissue letter).  These PMRs are prospective (3033-1) and retrospective (3033-2) epidemiologic studies that examined the serious risks and predictors of misuse, abuse, addiction, and fatal and non-fatal opioid overdose in patients with long-term use of opioid analgesics for management of chronic pain, including patients prescribed ER/LA OAs.

Registration is not necessary.

View Upcoming FDA Meetings, Conferences and Workshops

Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts.

About Us

The Public Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs.  We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations.  For more information, please contact us at: PublicEngagement@fda.hhs.gov.  For patient specific inquiries, please contact us at: Patients Ask FDA.